Paramagnetic nanoparticle
View Patent ↗The present invention relates to the preparation and use of nanoparticles, in particular paramagnetic nanoparticles, and their use as contrast enhancers for NMR-based methods of examination. A significant increase in contrast (e.g. from 100 to 200%) takes place according to the invention. An aqueous or organic synthesis leads to small nanoparticles which have a narrow size distribution and can also be advantageously used for many other industrial applications.
1. A method for the diagnostic examination of a patient comprising the steps of:
a) incorporating into a carrier paramagnetic nanoparticles having a lattice structure comprising anionic and cationic components, the cationic component comprising gadolinium ions, and the anionic component selected from borates, aluminates, gallates, silicates, germinates, phosphates, halophosphates, arsenates, vanadates, niobates, tantalates, sulfates, tungstates, molybdates, halides and nitrides, wherein the nanoparticles have a size of 1 to 20 nm with a standard deviation of less than 30%,
b) administering said carrier comprising said paramagnetic nanoparticles to a patient, orally or by intravenous injection, and
c) subjecting the patient to an NMR-based examination.
2. The method according to claim 1 , wherein said nanoparticles function as contrast agents or alter the relaxation time of a biological tissue to be examined in said patient.
3. The method according to claim 1 , wherein said carrier is a liquid.
4. The method according to claim 1 , wherein said NMR-based examination is selected from magnetic resonance tomography, magnetic resonance spectroscopy, magnetic resonance angiography, cardiac magnetic resonance tomography and magnetic resonance functional imaging.
5. The method according to claim 1 , wherein the anionic component is selected from phosphates and vanadates.
6. The method according to claim 1 , wherein the nanoparticles have a size of 1 to 4 nm.
7. The method according to claim 1 , wherein said paramagnetic nanoparticles have fluorescence properties achieved by doping with a cationic component selected from samarium, neodymium, erbium and dysprosium.
8. A method for the diagnostic in vitro examination of a material comprising the steps of:
a) taking said material from a patient,
b) incorporating into said material paramagnetic nanoparticles having a lattice structure comprising anionic and cationic components, the cationic component comprising gadolinium ions, and the anionic component selected from borates, aluminates, galates, silicates, germinates, phosphates, halophosphates, arsenates, vanadates, niobates, tantalates, sulfates, tungstates, molybdates, halides and nitrides, wherein the nanoparticles have a size of 1 to 20 nm with a standard deviation of less than 30%, and,
c) subjecting said marked material to NMR-based examination.
9. The method according to claim 8 , wherein said material is selected from antibodies, tissue, cancer cells and inflammatory cells.
10. The method according to claim 8 , wherein the anionic component is selected from phosphates and vanadates.
11. The method according to claim 8 , wherein the nanoparticles have a size of 1 to 4 nm.
12. The method according to claim 8 , wherein said paramagnetic nanoparticles have fluorescence properties achieved by doping with a cationic component selected from samarium, neodymium, erbium, and dysprosium.
13. A contrast agent comprising paramagnetic nanoparticles having a lattice structure, said paramagnetic nanoparticles comprising anionic and cationic components, the cationic component comprising gadolinium, and the anionic component selected from borates, aluminates, gallates, silicates, germinates, phosphates, halophosphates, arsenates, vanadates, niobates, tantalates, sulfates, tungstates, molybdates, halides and nitrides, wherein the nanoparticles have a size of 1 to 20 nm with a standard deviation of less than 30%.
14. The contrast agent according to claim 13 wherein said nanoparticles are dispersed in a liquid carrier.
15. The contrast agent according to claim 13 wherein said contrast agent is a composition for oral administration or intravenous injection.
16. The contrast agent according to claim 13 wherein the anionic component is selected from phosphates and vanadates.
17. The contrast agent according to claim 13 wherein the nanoparticles have a size of 1 to 5 nm.
18. The contrast agent according to claim 17 wherein the nanoparticles are gadolinium phosphate nanoparticles.
19. The contrast agent according to claim 13 wherein said paramagnetic nanoparticles have in addition fluorescence properties achieved by doping with another cationic component.